Tissue-agnostic Efficacy of Trastuzumab Deruxtecan (T-Dxd) in Advanced Solid Tumors with HER2 Amplification Identified by Plasma Cell-Free DNA (cfdna) Testing: Results from a Phase 2 Basket Trial (HERALD/EPOC1806).
JOURNAL OF CLINICAL ONCOLOGY（2023）
Key words
Intratumor Heterogeneity
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined